Results 231 to 240 of about 2,857,482 (280)

Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records. [PDF]

Front Digit Health
Robert PA, Denck J, Do CT, Ozkirimli E, Jamois C, Corso C, Wang K, Berger CT.   +7 more
europepmc   +1 more source

The Immuno-oncology-Induced Cytokine Release Syndrome Patient Diary: A Content-Valid, Patient-Reported Outcome Measure. [PDF]

Oncol Ther
Wells ET, Lucats L, Abbadessa G, Turnbull J, Talavera JR, Van Tomme SR, Cordero P, Arnould B, Reaney M, Coulouvrat C.   +9 more
europepmc   +1 more source

Digital Biomarkers of Cytokine Release Syndrome: Scoping Review and Ontology Development of the Role and Relevance of Digital Measures Using a Mixed Methods Approach. [PDF]

J Med Internet Res
Medberry CJ, Angel CZ, Batavia AS, Bradley S, Camerlingo N, Chen M, Datoo M, Kamdar P, Koenig E, Kusters L, Marquez C, Nukala U, Pettinati M, Phillips R, Sanchez DP, Shafagati N, Siegelman J, Stewart M, Varga C, Vandendriessche B, Wilkes M, Wolff-Hughes DL, Zahavi D, Zorman S, McClenahan SJ.   +24 more
europepmc   +1 more source

A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review. [PDF]

Clin Pharmacol
Yang J, Shen Q, Ke X, Liu W, Yang P.
europepmc   +1 more source

Machine learning-based predictive model for high- grade cytokine release syndrome in chimeric antigen receptor T-cell therapy. [PDF]

Front Immunol
Yu X, Wang Q, Halimulati T, Lv J, Zhou K, Chen G, Yin L, Liu Y, Bi J, Xiang Z, Wang Q.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Druggable Targets in Cytokine Release Syndromes

Clinical Cancer Research, 2023
Summary Bispecific T-cell engagers and chimeric antigen receptor T cells share the problem of eliciting acute systemic inflammation episodes known as cytokine release syndrome. Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without ...
Carlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, Pedro Berraondo, Ignacio Melero   +4 more
openaire   +2 more sources

Cytokine Release Syndrome Biology and Management

The Cancer Journal, 2021
Abstract The successful application of chimeric antigen receptor (CAR) T cells for the treatment of relapsed and refractory B-cell malignancies has ushered in a new frontier for the immunotherapy of cancer. Despite its successes, CAR T-cell therapy presents several challenges.
Dustin A, Cobb, Daniel W, Lee
openaire   +2 more sources

Cytokine Release Syndrome and Sepsis

Infectious Disease Clinics of North America, 2022
Both cytokine release syndrome (CRS) and sepsis are clinical syndromes rather than distinct diseases and share considerable overlap. It can often be challenging to distinguish between the two, but it is important given the availability of targeted treatment options.
Janhavi, Athale, Lindsay M, Busch, Naomi P, O'Grady   +2 more
openaire   +2 more sources

Modeling cytokine release syndrome

Nature Medicine, 2018
Complete leukemic responses to chimeric antigen receptor–modified T cells are invariably accompanied by severe toxicity. Recently developed animal models allow mechanistic dissection and prevention of toxicity without loss of therapeutic benefit.
Cliona, Rooney, Tim, Sauer
openaire   +2 more sources